Novo looks at Victoza in fatty liver disease; FDA flags SGLT2 inhibitors for potentially high blood acid levels;

> Novo Nordisk ($NVO) is examining recent clinical trial data that show its diabetes drug Victoza has potential as a treatment for fatty liver disease. Report

> A new lawsuit claims Blue Cross has withheld hep C cure Harvoni for financial reasons. Release

> The FDA has warned that a new class of Type 2 diabetes drugs--SGLT2 inhibitors--may cause dangerously high levels of blood acids that could require hospitalization. Report

> A lawsuit claims the FDA overstepped its bounds by deciding two generic drugs used to treat ADHD should no longer be substituted for Johnson & Johnson's ($JNJ) widely used Concerta. More

> Boehringer Ingelheim has new Phase II study data for idiopathic pulmonary fibrosis (IPF) treatment Ofev that show its efficacy and safety in a broader range of patients. More

And Finally... Australia's Sirtex may be on Bayer's M&A radar as the two companies focus in on radiation treatments for liver cancers. Story

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.